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Abstract 
Background: CLN2 disease (Neuronal Ceroid Lipofuscinosis Type 2) is an ultra-rare, neurodegenerative lysosomal 
storage disease, caused by an enzyme deficiency of tripeptidyl peptidase 1 (TPP1). Lack of disease awareness and the 
non-specificity of presenting symptoms often leads to delayed diagnosis. These guidelines provide robust evidence-
based, expert-agreed recommendations on the risks/benefits of disease-modifying treatments and the medical 
interventions used to manage this condition.
Methods: An expert mapping tool process was developed ranking multidisciplinary professionals, with knowledge 
of CLN2 disease, diagnostic or management experience of CLN2 disease, or family support professionals. Individu-
als were sequentially approached to identify two chairs, ensuring that the process was transparent and unbiased. A 
systematic literature review of published evidence using Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidance was independently and simultaneously conducted to develop key statements based 
upon the strength of the publications. Clinical care statements formed the basis of an international modified Delphi 
consensus determination process using the virtual meeting (Within3) online platform which requested experts to 
agree or disagree with any changes. Statements reaching the consensus mark became the guiding statements within 
this manuscript, which were subsequently assessed against the Appraisal of Guidelines for Research and Evaluation 
(AGREEII) criteria.
Results: Twenty-one international experts from 7 different specialities, including a patient advocate, were identified. 
Fifty-three guideline statements were developed covering 13 domains: General Description and Statements, Diagnos-
tics, Clinical Recommendations and Management, Assessments, Interventions and Treatment, Additional Care Consid-
erations, Social Care Considerations, Pain Management, Epilepsy / Seizures, Nutritional Care Interventions, Respiratory 
Health, Sleep and Rest, and End of Life Care. Consensus was reached after a single round of voting, with one excep-
tion which was revised, and agreed by 100% of the SC and achieved 80% consensus in the second voting round. The 
© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which 
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or 
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line 
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco 
mmons. org/ publi cdoma in/ zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Open Access
*Correspondence:  s.mole@ucl.ac.uk
†Joint first author: Sara E. Mole and Angela Schulz
1 University College London, London, UK
Full list of author information is available at the end of the article
Maurizio Scarpa: Coordinator of European Reference Network MetabERN; 
Nicola Specchio: Member of European Reference Network EpiCARE.
Page 2 of 19Mole et al. Orphanet J Rare Dis          (2021) 16:185 
Background
CLN2 disease comes under the umbrella of the Neuronal 
Ceroid Lipofuscinoses (collectively referred to as Bat-
ten disease), or historically and specific to CLN2 disease, 
Jansky–Bielschowsky disease. These are a clinically and 
genetically heterogeneous group of neurodegenerative 
disorders, with the age of onset predominantly in child-
hood [1].
Epidemiological data across all the NCLs are difficult 
to interpret. NCLs are classified according to the under-
lying gene defect, which may share similar clinical fea-
tures of visual loss, seizures, loss of motor and cognitive 
function, and early death [2]. CLN2 disease previously 
referred to as late-infantile neuronal ceroid lipofuscinosis 
(LINCL) (OMIM # 204500) due to its usual presentation, 
is an autosomal recessive disorder, caused by pathogenic 
variants in the TPP1 gene on chromosome 11p15 (EC 
3.4.14.9). Incidence and prevalence of CLN2 disease are 
poorly reported in the literature with one reference quot-
ing 6–8 cases per 100,000 live births [3], although geo-
graphical variation occurs [2, 4, 5]. Mutations associated 
with CLN2 disease include splice-junction mutations, 
missense mutations, nonsense mutations, small deletions 
and single-nucleotide insertions [6]. This results in either 
reduced activity or inactivation of the lysosomal enzyme 
tripeptidyl peptidase 1 (TPP1) [7], causing the accumula-
tion of ceroid lipofuscin in the lysosomes, massive glial 
activation and neuronal loss [8]. Ultrastructural analysis 
of lysosomal storage in CLN2 disease reveals a typical 
curvilinear profile pattern [9, 10]. The expression of TPP1 
is developmentally controlled, reaching peak expression 
at 2–4  years of age, when the onset of signs and symp-
toms of late infantile neuronal ceroid lipofuscinosis 
(CLN2, LINCL) typically manifest [11]. Early symptoms 
include new-onset seizures and ataxia, typically in com-
bination with a history of language delay [12].
To confirm a clinical suspicion of CLN2 disease, the 
recommended gold standard for laboratory diagnosis 
is the demonstration of deficient TPP1 enzyme activ-
ity (in leukocytes, fibroblasts, or dried blood spots) and 
the identification of pathogenic variants in both alleles 
of the TPP1/CLN2 gene [13]. When it is not possible to 
perform both analyses, either demonstration of deficient 
TPP1 enzyme activity in leukocytes or fibroblasts, or 
detection of two pathogenic variants in trans is diagnos-
tic for CLN2 disease [12]. Limited access to resources in 
certain regions can lead to a complex diagnostic journey 
[12]. This causes disjointed care and treatment delay for 
patients. In the recent past, disease management has 
been to treat symptomatically and palliatively [7]. How-
ever, the enzyme replacement therapy cerliponase alpha 
(Brineura®, BioMarin Pharmaceutical Inc.) was approved 
by the FDA and EMA in 2017, following efficacy in atten-
uating the progression of disease in affected children 
[14]. Further clinical trials are monitoring its continued 
effectiveness as well as efficacy in younger pre-sympto-
matic children. Faster diagnosis may allow children to 
be treated earlier in the disease or even pre-symptomati-
cally. An early diagnosis also allows timely genetic advice 
to be offered to the family.
Internationally agreed guidelines, supported by an 
expert faculty, formed by robust methodology and 
assessed by independent assessors, are essential. “Clini-
cal Practice Guidelines serve as a great equaliser in the 
field of rare diseases: as a matter of fact, they can mean 
the difference between no care/substandard care and 
patients living longer, healthier lives with fewer compli-
cations” [15].
Health questions to be answered by these guidelines
The five main health questions that these guidelines seek 
to answer are;
1. How can early identification and diagnostics for 
patients affected by CLN2 disease be improved?
2. How can the common manifestations encountered 
by patients and their families affected by CLN2 be 
improved?
3. Which supportive therapeutic options are currently 
available, and what is the expert consensus on their 
appropriate use?
4. Which disease modifying therapeutic options are 
currently available, and what is the expert consensus 
on their appropriate use?
5. What are the current knowledge gaps facing clini-
cians and families affected by CLN2 disease?
overall AGREE II assessment score obtained for the development of the guidelines was 5.7 (where 1 represents the 
lowest quality, and 7 represents the highest quality).
Conclusion: This program provides robust evidence- and consensus-driven guidelines that can be used by all 
healthcare professionals involved in the management of patients with CLN2 disease and other neurodegenerative 
disorders. This addresses the clinical need to complement other information available.
Keywords: Expert mapping, Guideline development program, CLN2, Batten, Neurodegenerative disorder, Key 
Opinion Leader, Modified-Delphi
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Objectives
Although recommendations for treating and managing 
CLN2 disease are available, the methodology used to for-
mulate these clinical recommendations has come under 
increased scrutiny, highlighting the need for robust, inde-
pendent guidance on the risks/benefits of disease-mod-
ifying treatments and the medical interventions used to 
manage this condition in the context of worldwide preva-
lence. The purpose of these guidelines is to provide com-
prehensive guidance for the identification and clinical 
management of patients with CLN2, independent of age 
and disease severity. This programme provides vigorous 
evidence-based and expert-agreed practical recommen-
dations to address the real clinical need for timely diag-
nosis, management and treatment of patients with CLN2 
disease. A validated modified-Delphi methodology was 
used which complemented other published information 
available. Two experts (Co-chairs) were selected to lead 
the project via the expert mapping tool described. This 
tool identified rare disease experts from across the globe 
who were approached to lead on a guideline development 
program for CLN2 disease. The anticipated benefit of 
this tool is that it may be utilised for other rare disorders, 
identifying the most appropriate experts to lead guide-
line development programs, removing selection bias with 
simple methodology.
The steps are time-consuming and not easy to accom-
plish. However, the need for finding these experts in 
this field is crucial. Key Opinion Leader (KOL) tools are 
not frequently published, and the methodology is infre-
quently shared.
The guideline program was led by an independent mul-
tidisciplinary Steering Committee (SC), recommended 
by the co-chairs.
All outputs and recommendations were independent 
of external stakeholder influence. The driving role of the 
SC was to validate the program process, inform on the 
objectives, lead the development of questions, and make 
practical recommendations that can be readily translated 
to benefit local clinical practice. These guidelines are 
intended for use by healthcare professionals who manage 
the holistic care of patients; with the intention to improve 
disease awareness, clinical outcomes and enhance patient 
quality of life. In addition, they are intended to be held by 
families who will enable non-expert health care provid-
ers to become aware of CLN2 disease, further empower-
ing all parties to support the management of individual 
patients.
Methods and process
Expert mapping tool development
In order for the expert mapping tool to identify such 
experts, a four-stage process was pursued: Relevant 
Publication Experience, Author’s H-Index, Patient 
Organisation Event attendance as a chair or speaker, 
and Scientific Event attendance as a chair or speaker. 
Each stage was followed methodically and consecu-
tively to ensure reproducibility.
The first stage is designed to capture the highest level 
of input into the current literature for CLN2 disease. 
PubMed database was interrogated using predeter-
mined search terms, and resulting publications were 
subsequently screened for relevance to CLN2. Selected 
publications were tracked, and all listed authors were 
sorted according to the number of appearances. 
Authors who appeared in two or more publications 
were selected and ranked as follows: two or more publi-
cations (score 1), 3–5 publications (score 2), 6–9 publi-
cations (score 4) and > 10 publications (score 5).
The second stage determines the authors H-index 
[16]. Any search engine such as SCOPUS, Publish or 
Perish, or Google Scholar can be used, although the 
same engine must be used for all investigators through-
out the process, for consistency. Authors were searched 
by last name, and first name and their profiles were 
found based on their occupation, middle initial, city 
and country of residence. The H-index result for each 
author was ranked as < 30 (score 3), or > 30 (score 9).
Stage three identifies individuals perceived as lead-
ing experts among families and advocates. An online 
search of publicly available information was conducted 
for experts who have been involved in patient organisa-
tion events or conference programmes during the pre-
vious 5-years. Search terms were CLN2, Batten disease 
and Neuronal Ceroid Lipofuscinosis. All chairs and oral 
presenters were recorded and cross-referenced with the 
Batten Disease Family Association, UK (BDFA), Bat-
ten Disease Support and Research Association, USA 
(BDSRA) and other CLN2 focused organisations. All 
oral presenters, poster presentations and chairs were 
tallied and ranked as either < 3 appearances (score 6), 
or > 3 appearances (score 9).
The final stage reveals those in the field perceived 
as experts by their peers and whose expertise is most 
called upon by the medical community to present their 
knowledge on CLN2 disease. A search was conducted 
for all scientific meetings that had a relevance to, or 
overlapping focus to CLN2, during the previous 5 years 
(Additional file 1: Appendix 1). Event programmes were 
reviewed to identify the speakers and chairs relating 
to NCL disorders. The number of appearances were 
recorded and ranked as 2–5 appearances (score 2), 6–9 
appearances (score 4) and > 9 appearances (score 6).
The weighted scores of each of the four stages were 
totalled, creating a new ranking of experts. Those who 
did not feature in multiple rounds or those with a ranking 
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score of < 10 were not considered. Within the final list, 
animal experts and industry professionals were not con-
sidered for chair positions. To remove bias, both cur-
rently practising and retired clinicians who have worked 
directly with CLN2 patients were included. Also, in order 
to remove bias, drive international collaboration and 
fill knowledge gaps, it was proposed that one chair was 
from Europe and the other from the rest of the world. 
The exception to this criterion was to review the list of 
leading clinicians, and once the geographic contrast was 
exhausted, all the experts on the list were considered in 
order of total score, regardless of geographical location. 
Full data analysis for the Expert Mapping Tool has been 
presented elsewhere [17] (Additional file 1: Appendix 2).
Convening the Steering Committee
The expert mapping tool identified two co-chairs, who 
then debated over which specialities were needed to best 
encompass all aspects of disease management. The SC 
was then selected based on their long-standing patient 
organisation involvement, combined with their academic 
output, covering the entire scope of the guidelines.
A list of 21 Steering Committee experts from Argen-
tina, Australia, Brazil, Germany, Ghana, Italy, United 
Kingdom and the U.S.A., contributed to the guideline 
development. These experts comprised seven speciali-
ties: geneticists, paediatric neurologists, neurosurgeons, 
paediatricians, nurses, physiotherapists, epileptologists, 
and one patient advocate from the Batten Disease Sup-
port and Research Association (BDSRA). The SC was led 
by the two co-chairs, who advised and drove the program 
and advocated the program. Further details, including 
the competing interests, institutions and contribution of 
each SC member are listed within the declarations sec-
tion of this manuscript.
Systematic literature review methodology
Running parallel to the expert mapping tool and SC 
selection, two systematic literature reviews were 
independently conducted by one internal, and one 
contracted medical writer, focusing on accumulat-
ing current evidence for treatment and management 
of CLN2 disease. Results were reported in accord-
ance with the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) statement 
[18]. Each literature search was performed in Febru-
ary and March 2019, respectively, through the Google 
Chrome browser, using PubMed and Google Scholar, 
and interrogation of internal CBD literature libraries. 
Both searches were set to the same search criteria to 
include: publications since 1970, both human and ani-
mal trials, grey literature, and full-text. English articles 
only were selected as the experts noted from recent 
literature reviews that the articles published in other 
languages around CLN2 are few and that it was also dif-
ficult to distinguish CLN2 from other NCL disorders. 
Search strings incorporated Medical Subject Headings 
(MeSH): ceroid lipofuscinosis-neuronal and late infan-
tile ceroid lipofuscinosis, Batten disease, Jansky–Biels-
chowsky. Free text keywords were defined based on 
Problem/Patient/Population, Intervention/Indicator, 
Comparison, Outcome (P.I.C.O.) methodology [19–21] 
to answer each of the clinical questions (Additional 
file  1: Appendix  3). The types of literature included 
were: systematic reviews, meta-analyses, reviews, chart 
reviews, descriptive observational studies (such as case 
reports, case series, patient registry data), and inter-
ventional early phase non-randomised and open-label 
clinical trials. Bibliographies of identified publications 
and reviews were checked for additional relevant stud-
ies, and all steering committee members were invited to 
provide publications that the literature reviews had not 
retrieved. The extracted details from included articles 
were: general focus (genetics, diagnostics, clinical man-
agement, therapy), study design, patient population, 
intervention or exposure, comparison (if applicable), 
outcomes and limitations. Publications were excluded if 
they were not specifically related to CLN2 disease, ani-
mal studies, preclinical studies and single case reports 
(full exclusion list Additional file  1: Appendix  4). One 
co-chair (AS) wrote the first draft of the clinical care 
statements, which were subsequently used for the first 
consensus-building meeting. The credible link between 
these publications and the draft statements was veri-
fied by an internal medical writer, who used the Oxford 
Centre for Evidence-Based Medicine (OCEBM) crite-
ria [22, 23] to assess each piece of literature that was 
linked to each existing statement and assigned a grade 
(Additional file  1: Appendix  5). One co-chair (SM) 
also independently assigned an OCEBM grade to each 
publication and cross-referenced the grades to those 
assigned by the internal medical writer. A member of 
the SC was appointed by this co-chair to independently 
assign OCEBM grades to the literature and review the 
grades previously assigned. Both the co-chair and the 
SC member independently identified any articles or 
evidence that was missing from each statement. The 
average grades for each article were taken, and then 
the ratings of each article which related to each state-
ment were averaged to give an overall evidence grade 
for each statement.
Consensus building: statement development meeting.
Steering committee members were invited to join an ini-
tial virtual meeting hosted on the Within3 online hosting 
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platform [24], which was used to establish the SC’s com-
munication preferences, biographies, conflict of interest 
statements, their availability during the programme and 
suggestions for further committee members. Within3 is a 
virtual 24/7 environment allowing stakeholders to inter-
act on their own schedule while allowing chairpersons 
to organise materials in one secure place, post feedback 
and answer questions. The platform includes an archiv-
ing facility.
In a second Within3 meeting the drafted statements 
were uploaded for the consensus-building phase of the 
guideline development program. The Within3 session 
has required resources which, in order to satisfy the 
requirements of the virtual meeting, must be opened and 
reviewed.
Medical guidelines have recently been developed which 
used literature to drive the main topics; these have sub-
sequently been adopted in these guideline statements 
[25]. The topics in those guidelines, the strength of our 
updated systematic literature reviews, and the invitation 
for each steering committee member to add any topics 
they felt should also be included or exclude any topics, 
ensured that current evidence was included and that no 
relevant topic was omitted. This is especially pertinent in 
rare disease disorders where research is scarce.
A text bar was provided to enable the experts to record 
their recommended changes to each statement. The sur-
vey session was open for 19 days to allow the entire SC 
the opportunity to participate and respond to the feed-
back of others. Reminders were sent out during the 
19 days to encourage continued activity.
Modified Delphi Questionnaire: Health care professionals
Guideline statements resulting from the modified-Delphi 
questionnaire were systematically validated through an 
anonymous voting process on Surveylet, a collaborative 
research software by Calibrum (https:// calib rum. com). 
Healthcare professionals (HCPs) recommended by the 
SC were invited to participate through a live link and 
online survey. This process collected the perspectives of 
all relevant HCPs. In the first round of voting HCPs were 
asked: whether they had ever managed a CLN2 patient, if 
so, how many; whether their understanding of the Eng-
lish language was sufficient to complete the survey; their 
primary role, their main area of expertise, length of time 
in practice, type of primary practice and in which coun-
try. Experts were also asked if they had previously been 
involved in guideline development groups. The goal was 
to collect over 60 responses from at least six different 
specialities responsible for managing patients with CLN2 
disease.
The HCPs were asked to validate the guideline state-
ments based on the CLN2 community expert consensus. 
Each guideline statement was graded via Likert-type scale 
1–10, where 1 totally disagreed, and 10 strongly agreed. 
Consensus was taken at ≥ 75% agreement or more on 
each statement as the most commonly reported defini-
tion of consensus for Delphi studies is per cent agree-
ment, with 75% being the median threshold to define 
consensus [26, 27].
Where consensus was not reached, the statement was 
revised by the SC chairs as they felt some simple seman-
tic changes were all that was required to resolve this. If 
a statement received polarising views, a subject matter 
expert was invited to present on the topic. Statements 
that reached the consensus mark were included in this 
manuscript and were not changed. The survey was left 
open for eight weeks to collect as many responses as 
possible.
Quality assessment
The AGREEII instrument was used [28] by two inde-
pendent reviewers to assess the quality of the guideline 
development strategy and reporting. This validated tool 
consists of 23 items divided into six domains: Scope and 
Purpose, Stakeholder Involvement, Rigour of Develop-
ment, Clarity of Presentation, Applicability and Edito-
rial Independence. Each item is rated on a scale from one 
(criteria not met) to seven (criteria fully met). Suggested 
amendments were made where possible; a subsequent 
second round of review was conducted, and the average 
of the two review rounds reported. Combined scores for 
each domain were calculated using the following equa-
tion (obtained score-minimum possible score)/(maxi-
mum possible score) × 100. An overall average score was 
calculated from a maximum value of 7.
Results
Expert mapping tool
The expert mapping tool identified 1454 professionals, 
who were sequentially approached after ranking until 
two were able to commit to participation in this project 
as chairs. Although the expert mapping tool recommends 
that one chair should be European and another from the 
rest of the world, on this occasion, due to the availability 
of experts, it was not possible. The expert mapping lit-
erature review resulted in 155 relevant publications, with 
717 published authors, of whom 124 were scored. The 
highest scored expert was 21, and the lowest was 1. The 
two selected co-chairs had individual scores of 20 and 16.
Systematic literature review
The systematic literature review conducted by the con-
tracted medical writer identified 4122 publications. Fol-
lowing the removal of duplicates and exclusion criteria 
applied, 350 publications were screened and 160 further 
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excluded. Qualitative analysis and PICO summaries 
were completed for 190 papers. The systematic literature 
review conducted by the internal medical writer identi-
fied 11,996 publications. Following the removal of dupli-
cates and exclusion criteria, 342 were screened and 158 
further excluded. Qualitative analysis and PICO sum-
maries were completed for 184 papers. (Additional file 1: 
Appendix 4, a,b, respectively).
Consensus building: statement development meeting.
During the initial Within3 [24] stage of the consensus 
process, the steering committee posted over 1200 com-
ments, and the collaborative discussion garnered align-
ment on the clinical care statements. The SC actively 
participated and responded to statements, which were 
reduced from 73 to 53 final clinical care statements. 
Members gravitated from opposing views to a shared 
perspective, leading to 53 revised statements created 
using the majority perspective.
Consensus building: Modified Delphi Questionnaire
Of the 41 experts who responded to the questionnaire, 
consensus ranged between 82 and 98%. 100% had man-
aged a CLN2 patient, and they all considered that their 
level of English was sufficient to complete the survey. The 
lowest number of respondents for any question was 35. 
Physicians made up 93% of the respondents, followed by 
nurse practitioners, physiotherapists and occupational 
therapists. Areas of expertise included: paediatric neu-
rologists (54%), metabolic specialists (20%), geneticists 
(9%), neurosurgeons (2%), paediatricians (6%) and oth-
ers (9%). While there was a good geographical spread 
of responses, 20% resided in the U.S.A. (Additional 
file  1: Appendix  6). Over 78% of respondents had been 
in clinical practice for over ten years, and over 97% were 
working in a large referral centre or academic hospital. 
When asked how many patients they had managed, 54% 
responded between 0–5, 20% 6–10, and 26% > 10, result-
ing in a wide range of experience managing CLN2 dis-
ease patients. There was no consensus on whether the 
experts had previously been involved in guideline devel-
opment, although 20% had no previous experience, 74% 
had been involved on 1–4 occasions, and only 6% were 
experienced. Of the 53 statements reviewed, 98% of the 
statements achieved consensus in the first round. Of the 
single statement that did not reach consensus, the Chairs 
revised the statement and launched the Modified Del-
phi 2 (second round) questionnaire. During this process, 
100% of the statements met the consensus benchmarks 
and were included in the guidelines.
Appraisal of Guidelines for Research and Evaluation (AGREE) 
II Assessment
The SC recommended other health care professionals 
(HCPs) who were independent of the process, to review 
the manuscript and identify gaps or areas of confusion.
Two external independent reviewers rated the meth-
odology against each the Appraisal of Guidelines for 
Research and Evaluation (AGREEII) criteria [28]. In 
each of the six domains, a percentage of 50% or higher 
was obtained. Individual scores were 83.3% for Scope 
and Purpose, 81.0% for Stakeholder Involvement, 65.2% 
for Rigour of Development, 83.3% for Clarity of Presen-
tation, 50% for Applicability, (which resulted in a lower 
score due to one question being deemed not applicable, 
and therefore scored 1) and 78.6% for Editorial Inde-
pendence. The guidance documents were given an overall 
assessment score of 5.93 (Additional file 1: Appendix 7).
Guideline statements
Guideline statements were developed from the results of 
the systematic literature review as a starting reference, 
which revealed 13 different topics of clinical focus. The 
topics included: General Descriptions and Statements, 
Diagnostics, Clinical Recommendations and Manage-
ment, Interventions and Treatment, Assessments, Social 
Care Considerations, Pain Management, Epilepsy/
Seizures, Nutritional Care Interventions, Respiratory 
Health, Sleep and Rest, End of Life Care, and Additional 
Care Considerations.
General description of CLN2 disease and statements (Table 1)
Multiple forms of CLN2 disease exist. In the more com-
mon form of the disease patients present with slowing 
of development and psychomotor regression, language 
delay and typically followed by epilepsy between the ages 
of 2 and 4 [29], subsequently developing retinal degen-
eration and blindness by 5 or 6  years of age [30]. Life 
expectancy is between 6 and early teenage years [20]. 
Around 13% of patients have a later symptom onset [31], 
more protracted or mild disease course sometimes with 
the absence of epilepsy and preservation of visual func-
tion and a longer life expectancy [12, 32]. Genotypes 
from these atypical patients predict reduced, rather than 
the absence of TPP1 activity. Alternatively, TPP1 activity 
may be absent in certain cell types, but residual activity 
may remain in leukocytes [33]. Reduced TPP1 activity 
is implicated in other heterogeneous autosomal reces-
sive ataxias such as SCAR7 the phenotype previously 
described as Type 7 Autosomal Recessive Spinocerebellar 
Ataxia or other atypical presentations of CLN2 disease 
[34]; thus the diagnostic workup for unexplained spi-
nocerebellar ataxias should also include analysis of TPP1 
enzyme activity.
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Clinicians should, where possible, provide every family 
with detailed diagnostic, biochemical and genetic infor-
mation. Four statements were developed to support the 
general description of CLN2.
Diagnostics (Table 2)
The diagnosis and management of CLN2 disease remain 
ongoing challenges due to low disease awareness, non-
specific presenting symptoms and poor access to diag-
nostic testing in certain regions [5]. Late-infantile CLN2 
disease should be considered in young children with 
delayed acquisition of, or decline in, language and new 
onset of seizures [35].
Diagnostic methods have evolved considerably over 
the last 30  years. Traditionally, electron microscopy of 
muscle [36], skin and conjunctival biopsies [37] provided 
valuable diagnostic information. Ultrastructural diagno-
sis by using biopsies requires the support of clinical and 
electrophysiological findings [38], but for CLN2 disease 
this has now been superseded by enzyme testing remov-
ing the need for these more invasive and lengthy tests. 
Ultrastructural examination of peripheral blood lympho-
cytes in the NCLs reveals different specific cytoplasmic 
inclusions, with curvilinear profiles typically occurring in 
classic CLN2 disease [39–41], which were used in prena-
tal diagnosis using electron microscopy [42, 43]. The first 
successful prenatal test using DNA and enzyme-based 
methods on amniocytes was reported in the early 2000’s 
[44], and a little later by enzyme and mutational analysis 
of first-trimester chorionic villi [45]. Molecular analysis 
with allele-specific primer extensions can facilitate pre-
natal diagnosis, where the familial mutation is known 
[46].
Specific polyclonal antibodies against TPP1 detect the 
absence or marked reduction of this protein in lympho-
cytes, lymphoblasts, fibroblasts [47] and brain homogen-
ates [48] from LINCL patients, a technique found to be 
accurate, cost-effective, and rapid.
Early laboratory diagnostic methods required the 
support of neuroradiological findings. Marked cerebel-
lar atrophy is visible at an early stage of CLN2 disease 
[49]. Neurophysiological findings are characteristic for 
classic late infantile CLN2 disease, with early presen-
tation of a typical paroxysmal spike‐wave response in 
response to low frequency intermittent photic stimu-
lation (IPS, 1–2  Hz) (the photoparoxysmal response 
Table 1 General description of CLN2 disease, statements and consensus data
Statement Responders Evidence 
level
Consensus 
%
Within CLN2, two forms of disease evolution exist; classical CLN2 is where symptoms start earlier, between 
the ages of 3 and 5 years and the symptoms evolve faster. While Non-classical CLN2 has a much slower 
disease evolution and symptoms appear as behavioural disorders, movement disorders and ataxia 
rather than seizures and blindness
41 C 82
Classical CLN2 disease is currently also known as late infantile ceroid lipofuscinosis (LINCL). The classical 
term Jansky–Bielschowsky disease has a historical value. Batten disease is the umbrella/category term 
and should be used to regard to all NCL and for clarity for the individual disorders refer to the associated 
gene
40 D 82
Several phenotypes exist within the spectrum of TPP1-deficiency-related diseases. While one (classic CLN2 
disease) is far more common than the others, there is overlap in care/ treatment and patient support
41 C 82
These Guidelines will cover the whole spectrum of disorders caused by mutations in CLN2/TPP1, includ-
ing those with phenotypes not typically classed as NCL
25 NA 80
Table 2 Diagnostic statements and consensus data
Statement Responders Evidence 
level
Consensus 
%
Diagnosis of CLN2 during infancy is critical to optimise patient outcomes which would benefit by new-
born screening
41 D 85
Patients with the existence of a significant speech delay or decline, clumsiness and undiagnosed/unat-
tributed epilepsy before the age of 4 should be tested for CLN2 Disease
40 D 92
The diagnosis of CLN2 can be confirmed by low levels of TPP1 enzyme activity and should be double 
confirmed by detecting two disease-causing mutations in the CLN2 gene
40 C 91
Early diagnosis as soon as possible after or before symptom onset is crucial and is done by biochemical 
testing following unprovoked seizures and or unsteadiness in children who may also present delay/
decline in psychomotor development, including speech delay
40 B 88
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(PPR)) by electroencephalogram (EEG) [50, 51]. This 
early photosensitivity is a hallmark of CLN2 disease, 
particularly if accompanied by delayed speech and/or 
ataxia [52]. Diminished EEG and enhanced cortical vis-
ual evoked potentials (VEP) are seen in the later stages 
of disease [52]. In contrast, vision loss occurs later in 
the disease of CLN2 that other NCL subtypes and is 
not a clinical hallmark for diagnosis [53]. International 
experts had met in 2015 and recommended best lab-
oratory practices for early diagnosis of CLN2 disease 
[12]. In any family with a hereditary metabolic brain 
disorders, early or prenatal diagnosis is paramount 
both for clinical management, maximising the benefit 
from therapies, and for the adjustments in family life-
style and future family planning [54]. The genetic het-
erogeneity in NCLs demonstrates the importance of 
DNA testing to accurately identify affected individuals 
and carriers [55].
Four statements were developed to support the cur-
rent recommendations of diagnostic methods.
Clinical Recommendations and Management of CLN2 disease 
(Table 3)
Management of CLN2 disease should be guided by 
the standards and guidelines from the International 
Children’s Palliative Care Network [56] with a holis-
tic approach to supporting both the patient and 
their families. This requires a skilled multidiscipli-
nary paediatric team of physicians, nurses and thera-
pists, dieticians, psychologists, social workers and 
counsellors [25]. Supportive behavioural and symp-
tomatic treatments, including anti-epilepsy medi-
cation, are warranted [20, 57]. Six statements were 
developed to support the clinical and management 
recommendations.
Assessments (Table 4)
A comprehensive medical history and multisystem 
evaluation should be conducted at the first clinic visit 
to evaluate the physical and neurological manifestations 
of the disease and establish a baseline for natural his-
tory assessments. This should include general health, 
growth, vital signs, age at onset, language and motor dif-
ficulties, behavioural abnormalities, seizure frequency, 
feeding issues, ophthalmic examinations, full neurologi-
cal evaluation and brain Magnetic Resonance Imaging/
Spectroscopy (MRI/MRS) [35, 58]. As part of the ini-
tial evaluation, some centres may find EEG with poly-
graphic recordings useful to detect the photoparoxysmal 
response [52]. Rating scales for neurological decline and 
imaging can provide valuable benchmarks for disease 
progression and severity [59]. Assessments should be 
ongoing and regular at each clinic visit, or as clinically 
indicated.
In order to evaluate disease progression clinically, the 
use of the Hamburg scale [60] is well validated to assess 
the regression of motor and language function as well as 
epilepsy and vision. The Weill Cornell LINCL scale is an 
adapted version of the Hamburg scale and adds the cat-
egory swallowing and myoclonus [58]. Both scales have 
been combined and definitions of scores edited in order 
to be used as efficacy measures in clinical trials.
Volumetric analysis of cortical grey matter loss, volume 
percentage of cerebral spinal fluid (%CSF) by MRI and, 
N-acetyl aspartate to creatinine ratios (NAA/Cr) from 
whole-brain MRS techniques, have been proposed as 
quantitative biomarkers of disease progression [61, 62].
Table 3 Clinical recommendations and management of CLN2, statements and consensus data
Statement Responders Evidence 
level
Consensus
All patients with suspected CLN2 disease should be referred to a centre with expertise in managing 
patients with NCL disorders
41 NA 95
The first consultation should be conducted by a physician with experience of treating CLN2, when 
possible, as soon as possible after diagnosis. This should include a full discussion of disease pathol-
ogy, progression, treatment options and management. Ongoing information should be provided to 
optimise patient outcomes
41 NA 95
A paediatric neurologist, rare disease specialist with clinical experience in CLN2 disease supported by a 
local multidisciplinary team, should lead the patient’s care
41 NA 89
Holistic care is critical for CLN2 management and a multidisciplinary team (MDT) is advised where pos-
sible to manage the diverse range of disease manifestations
41 B 96
Emotional and psychological family support should be recommended and offered by an appropriate 
health care provider to the patient, caregiver and full family
41 D 97
Psychological support or counselling should be offered/made available, where available to families 
following diagnosis and should be informed of relevant patient organisation contacts when deemed 
appropriate
41 NA 95
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While the relationship between neurological function 
and ophthalmic manifestations in CLN2 disease is not 
well defined, ophthalmic degeneration closely correlates 
with the degree of neurological function and the age of 
the patient [53]. Full-field ERG may be useful for NCL 
diagnosis, particularly for those who do not have access 
to genotyping [63]. Non-invasive assessment of ongoing 
macular and retinal degeneration can be performed by 
using optical coherence tomography (OCT) and quanti-
fied over time [53]. Age-appropriate ophthalmology eval-
uations are recommended every six months, along with 
patient-reported outcomes annually, or more frequently 
if necessary. Nine statements were developed to support 
the recommendations for clinical assessments.
Table 4 Assessments, statements and consensus data
Statement Responders Evidence 
level
Consensus
In order to monitor the disease progression, it is recommended that a patient receives baseline assessment 
to track disease progression, a series of tests where possible including EEG, Visual Exam, Epilepsy Record 
and Medication Utilisations, a record of MRI scans and cognitive testing. These exams focusing on physical 
and neurological manifestations should be repeated on an interval agreed to by the MDT (6 months or 
annually)
41 C 84
Currently, two tools are used for disease progression, namely the Hamburg Scale and the Unified Batten 
Disease Rating Scale, which are most widely used and accepted within the CLN2 Community
38 B 85
A comprehensive medical history and multi-system evaluation should be conducted following diagnosis 
and at parent and care providers discretion to set a baseline for ongoing assessments and evaluate the 
physical and neurological manifestations of disease, functional ability and disease burden
40 C 90
Ongoing and regular multi-system monitoring and assessments are recommended to track the natural 
history of CLN2, monitor the impact of treatment and assess the need for treatment interventions to man-
age the symptoms of CLN2. These should be conducted at every clinic visit, annually or in some cases as 
clinically indicated
41 D 90
A physical examination should be performed during every visit to assess general health, growth, vital signs, 
visual performance, frequency of seizures, developmental assessment and new significant medical events
41 NA 90
MRI of the brain is recommended at diagnosis if not already performed in patients with CLN2 and should be 
repeated as needed
40 D 89
Age-appropriate evaluations by an ophthalmologist are recommended every 6 months if possible, or at 
least annually
39 NA 92
Annual or more frequently if needed patient-reported outcomes is recommended to capture disease impact 
on patients and their families
40 NA 90
Regular therapy and assessments should be provided in a comfortable local setting agreed with the family 
by physiotherapists and speech therapists and anticipatory/timely provision of supportive devices, as well 
as regular therapy such as music therapy and other activities that reflect the interest of the patient
37 NA 95
Table 5 Interventions and Treatments for CLN2 disease, statements and consensus data
Statement Responders Evidence 
level
Consensus
Initiation of long-term ERT with cerliponase alfa at 300 mg (or age-appropriate) dose every other week 
through intraventricular infusion is suggested in non-classical TPP1 deficiency patients after confirmed 
diagnosis and agreement between parents and provider, as long as no contraindications to therapy 
exist. Initiation of long-term ERT with cerliponase alfa at 300 mg (or age-appropriate) dose every other 
week through intraventricular infusion is recommended in classical CLN2 patients with the potential to 
benefit from this therapy
37 C 84
Disease-modifying treatment with a licensed therapy ideally should be delivered by a team experienced 
in the management of CLN2 disease and use of any required devices. For current ERT treatment for 
CLN2 disease, this includes brain intraventricular devices
39 C 93
There is no evidence currently that HSCT benefits patients with CLN2 and at this time is not recom-
mended or approved as a treatment
34 C 93
Intraventricular devices should be placed under general anaesthesia by a very experienced paediatric 
neurosurgeon
36 C 92
Intraventricular device should only be accessed by a trained individual to limit/ minimise complications 39 C 95
Page 10 of 19Mole et al. Orphanet J Rare Dis          (2021) 16:185 
Interventions and treatments for CLN2 disease (Table 5)
Various treatment strategies are under clinical develop-
ment for the treatment of NCLs, although to date, there is 
only one clinically approved drug for CLN2 disease [64]. 
Recombinant human TPP1 (cerliponase alfa, Brineura™) 
is an enzyme replacement therapy (ERT) that slows the 
decline of motor and language function in CLN2 patients 
[14]. The approval of cerliponase alfa (2017) in the Euro-
pean Union (EU) covers all ages, and the Food and Drug 
Administration (FDA), for patients of 3 years and above 
[65]. Clinical trial evidence revealed that the therapy is 
well tolerated. As in other enzyme replacement therapies, 
the development of anti-drug antibodies (ADA) repre-
sents a constant risk for allergic reactions and—if anti-
bodies are neutralising—for loss of treatment efficacy. 
Although ADA production was detected in the cerebro-
spinal fluid (CSF) and serum, of 25% and 79% patients, 
respectively, this was not associated with neutralising 
antibodies, any incidence of hypersensitivity adverse 
reactions, or reduced therapeutic response [66].
Cerliponase alfa is administered every two weeks via 
slow intracerebroventricular (ICV) infusion (300  mg), 
using a Huber non-coring needle and syringe pump with 
post-infusion flushing of the line to ensure complete dos-
ing. This technique requires device implantation under 
general anaesthesia, by an experienced paediatric neu-
rosurgeon. General anaesthetic comes with an elevated 
risk of harm in the NCL population [67]. Extreme mus-
cle atrophy, seizures and upper airway obstruction add 
potential complications and may need to be managed 
accordingly by specialist anaesthetists. |A risk of signifi-
cant hypothermia under general anaesthetic is supported 
by a case study of a 14-year old child with CLN2 disease 
[68]. A further potential anaesthetic risk to this popula-
tion involves the pathology of the heart, which includes 
cardiomyopathy and repolarisation disturbances, 
described in older patients but which maybe evolving in 
younger patients [69].
Investigators recognise that combinational therapeutic 
approaches will be required to tackle the multiple whole 
body aspects of any NCL [70, 71] Current efforts are 
aimed at developing therapies that effectively attenuate 
neurodegeneration in both the brain and the retina [64]. 
Five statements were developed to support the recom-
mended interventions and treatments.
Table 6 Additional Care Considerations for CLN2 disease, statements and consensus data
Statement Responders Evidence level Consensus
CLN2 should be managed holistically by a multidisciplinary team to address and manage all 
symptoms of the disease
40 D 95
Fig. 1 A palliative care framework for CLN2 disease management facilitates comprehensive care of patients and families. Figure taken from Williams 
et al. [25] Management strategies for CLN2 disease. http:// dx. doi. org/ 10. 1016/j. pedia trneu rol. 2017. 01. 034. Published by Elsevier Inc. an open access 
article under the CC BY-NC-ND license (http:// creat iveco mmons. org/ licen ses/ by- nc- nd/4. 0/)
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Additional care considerations for CLN2 disease (Table 6)
As classic late infantile CLN2 disease progresses, there 
is a high symptom load and rapid rate of functional 
decline. The crucial goal is the maintenance of quality 
of life, for the patient and their family. Psychosocial sup-
port is imperative. A framework should be in place for 
comprehensive patient and family-centric care, which 
must evolve as the disease progresses (Fig. 1). Frequency 
of clinic visits should be tailored to meet the individual 
needs of the patient and their family. One statement was 
developed to support the additional care considerations.
Social care considerations for CLN2 disease (Table 7)
CLN2 disease has a profound impact on family life. The 
physician should be prepared for the reaction from family 
as the diagnosis often comes after a protracted diagnosis 
journey of two or more years. At the time of diagnosis, 
families should be provided with information, relevant 
resources and encouraged to ask questions. Contact 
details from patient advocacy groups should be offered 
to support all family members [20]. Engagement of the 
palliative care team is essential and must be managed 
on the basis of individual need, and in line with avail-
able resources. Genetic counselling and family planning 
should be offered. Grief and bereavement support should 
be ongoing, and memory-making activities encouraged 
[25].
Caregiver burden has a significant impact on families, 
and appropriate tools and adaptations should be put in 
place [72] to cope with the psychological stress, the phys-
ical impact from carrying and lifting, social challenges, 
and financial strain.
Although children with untreated CLN2 disease are 
typically unable to walk, talk and are visually impaired 
by the age of 6, hearing is preserved, and it is essential 
to maintain school attendance for as long as possible and 
continue social interactions. Good communication net-
works should be set up between parents, healthcare giv-
ers and school staff to create an environment where the 
child’s needs can be met at school. There should be a shift 
in the approach to an educative model which focuses on 
maintenance of functional abilities rather than gaining 
new ones. Augmentative communication, such as the use 
of objects of reference and gestures, can be beneficial and 
should be implemented early [25]. The high prevalence of 
behavioural symptoms causes distress to families, mainly 
because they may be indicative of disease progression 
[73]. Physical, occupational, speech and complementary 
Table 7 Social Care Considerations for CLN2 disease, statements and consensus data
Statement Responders Evidence level Consensus
Adaptations and support for communication is essential and a speech and language expert should be 
involved in all patients with CLN2
41 NA 92
Considerations should always be made in order to maintain a patient’s activity and social interaction by 
aiding their mobility, communication abilities, and special considerations around loss of vision
41 NA 95
Considerations to teach patient alternative communication strategies and strategies for utilising audio 
sense following vision dysfunction may assist a patient in their ability to socialise
40 NA 92
Early use of medical aids such as orthoses, therapy chairs, standing and walking equipment supports 
mobility which improves quality of life
41 NA 92
Caregiver burden has a significant impact on families affected by CLN2, and appropriate tools should be 
used to capture this
41 D 92
Visual support is critical to maintaining function, and all measures should be employed to maintain 
visual ability
41 NA 86
Physical, occupational, speech, and other supporting therapy interventions are recommended for 
patients in order to maintain activity and the highest of quality of life
41 D 94
Table 8 Management of movement disorder and pain in CLN2 disease, statements and consensus data
Statement Responders Evidence level Consensus
Mobilisation and repositioning can help reduce pain. Medical aids such as a standing device or systems 
for positioning in bed should be considered
40 C 93
There is a complex movement disorder in CLN2 disease that includes, but is not limited to, dystonia 
and involuntary muscle movements. Treatment approaches should be developed in cooperation by 
experts for NCL and movement disorders
40 C 90
In CLN2 complex movement disorder paired with a complex seizure phenotype and myoclonic jerks 
might mimic pain-like episodes that have a different origin (e.g. agitation, boredom, fear and even 
happiness) should be managed pro-actively according to the aetiology
40 C 90
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therapy interventions should be included in the care 
package [25].
Pain management and movement disorder in CLN2 disease 
(Table 8)
Assessing pain in CLN2 children is challenging because 
of their lack of language. Therefore patients should be 
assessed carefully for any possible cause for pain and 
treatment should be specified accordingly: Gastrointesti-
nal problems such as constipation and gastric reflux are 
frequent sources of pain. Also, urinary retention, skin 
breakdown, dental problems, hip luxation, bone fractures 
due to osteoporosis caused by immobility are all sources 
of pain in CLN2 disease. It is often difficult to distinguish 
between pain and other sources of discomfort: fear, anxi-
ety, loneliness or boredom [25]. The Batten’s Observa-
tional Pain Scale may be useful for parents monitoring 
their children’s pain at home [74]. Transdermal fentanyl 
has shown some efficacy in reducing centrally mediated 
pain [75].
The complex movement disorder phenotype associated 
with CLN2 disease includes non-epileptic myoclonus as a 
hallmark as well as dystonia, spasticity, chorea, athetosis, 
and tremors. These symptoms represent a high disease 
burden to the patient and are very difficult to control and 
can be aggravated by pain. Therefore, pain should always 
be treated first or ruled out. Advice from movement dis-
order experts is often helpful. Recommended pharmaco-
logic treatment includes benzodiazepines, phenobarbital, 
levetiracetam, pregabalin, valproate, lamotrigine, and 
zonisamide [25]. However, these should be selected care-
fully and periodically re-evaluated. Positioning aids, 
weighted blankets, physiotherapy, heat and medications 
may help to ameliorate pain [25]. Discomfort caused by 
spasticity can be effectively treated with physical therapy, 
baclofen and tizandine. Three statements were developed 
to support movement disorder and pain management 
recommendations.
Epilepsy and seizures in CLN2 disease (Table 9)
Multiple seizure types are observed in CLN2 disease, 
including myoclonic, tonic, atonic, absence and tonic–
clonic. The goal of seizure management is to minimise 
the impact of seizures on the child’s well-being, thereby 
supporting social interactions, mobility and fall preven-
tion [25]. Epilepsy in children with polymorphic seizures 
(including CLN2 disease) is largely therapy-resistant [76], 
and complete seizure freedom is most likely not possible 
to accomplish even with polytherapy. Certain AEDs such 
as carbamazepine and phenytoin have been reported to 
exacerbate myoclonus and should be avoided [20]. Other 
AEDs may have side effects similar to disease symp-
toms such as language impairments due to topiramate; 
therefore, these should be used with caution [25]. While 
valproate is the most commonly used medication in sei-
zure management, its long term use has also rarely been 
implicated in the exacerbation of dystonia in late disease 
stages [25], with associated hyperthermia and hyper cre-
atine kinase (CK)-aemia [77]. As the disease progresses, 
myoclonic seizures can predominate and are difficult to 
control [29]. Reports on the application of cannabis in 
paediatric epileptology have been widely published. The 
component tetrahydrocannabinol (THC) may reduce 
spasticity, improve dystonia, increases initiative and 
interest in their surroundings, and is anticonvulsive [78]. 
However, more recently, the compound cannabidiol has 
been shown to have fewer side effects and be more effi-
cacious in NCL patients [79]. To the expert’s knowledge, 
there is no table of recommended medications depend-
ing on the stage of disease progression. While a list of 
common medications used to treat CLN2 disease symp-
toms is reported in Williams et al. [25], of which they rec-
ommend periodic re-evaluation, further investigation is 
necessary for the optimisation of medication regimes for 
seizure management and movement disorder.
Children with CLN2 disease may be prescribed mul-
tiple drugs (between 10–12), and there should be an 
awareness of drug-drug interactions [25]. It is recom-
mended to minimise polypharmacy as far as possible. 
A ketogenic diet has also been shown to be effective in 
treating multiple seizure types [80] and in drug-resistant 
seizures, although patients should be closely monitored 
for side effects, such as constipation, kidney stones and 
growth retardation [25].
Seizures in CLN2 disease can be life-threatening, and 
emergency seizure management plans for home and 
Table 9 Epilepsy and seizures in CLN2, statements and consensus data
Statement Responders Evidence level Consensus
Epilepsy management should include consideration of the most 
appropriate medications for CLN2 disease and those AEDs that 
are not recommended
38 C 88
ALL recommended medication to be listed out in a table with a 
clinically suggested sequence depending on the stage of disease 
progression
38 NA 88
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school should be put in place. Medications for emergency 
use include buccal or intranasal midazolam, diazepam 
or lorazepam [25]. Two statements were developed to 
support the recommendations for epilepsy and seizure 
management.
Nutritional Care Interventions (Table 10)
Nutritional management is critical to patient care. 
Swallowing difficulties arise and worsen until oral food 
intake (eating and drinking) fails to meet nutritional 
requirements, and there is a high risk of aspiration. Car-
egivers should be educated on appropriate food consist-
encies and how to recognise and alert clinicians to early 
signs of oro-pharyngeal dysfunction. Pharmacological 
and non-pharmacological interventions can be recom-
mended to manage oral secretions [25]. Therapeutic 
support for orofacial regulation should commence as 
soon as swallowing difficulties occur, and maintained 
during tube feeding to reduce secondary damage. Even 
if the child has a feeding tube, it remains necessary to 
be able to swallow saliva and close the mouth. A step-
wise program of anticholinergic treatment is neces-
sary to minimise drooling, although side-effects such 
as constipation and urinary retention may be observed 
[25]. Regular intermittent, low-dose botulinum toxin 
injections to the salivary glands, may also help to con-
trol symptoms. Tube feeding is recommended when 
aspiration risk becomes high, and again families should 
be advised on gastrostomy tube home care and enteral 
feeding [25]. Three statements were developed to sup-
port nutritional care recommendations.
Respiratory health (Table 11)
Respiratory complications may quickly become life-
threatening, especially in the latter stages of CLN2 
disease. Vaccinations against preventable respiratory 
diseases are recommended for the whole family [25]. 
Table 10 Nutritional Care Interventions in CLN2, statements and consensus data
Statement Responders Evidence 
level
Consensus
Any patients affected by CLN2 should be fed according to his/her CNS grade of integrity, or there is no 
evidence to support feeding CLN2 patients different to any other patient affected by a neurodegenera-
tive disease
38 D 86
For CLN2 patients over age 16 years with significant dysphagia, enteral tube feeding should be consid-
ered according to current NICE guidance: https:// www. nice. org. uk/ guida nce/ cg32/ chapt er/1- Guida 
nce# enter al- tube- feedi ng- in- hospi tal- and- the- commu nity
35 NA 83
Tube feeding should be considered if one of the following is present: Increased risk of choking, Inability 
to meet nutritional requirements, Confirmed silent aspiration on video fluoroscopy, Repeated episodes 
of aspiration pneumonia confirmed by imaging
40 NA 94
Table 11 Respiratory health in CLN2, statements and consensus data
Statement Responders Evidence level Consensus
In CLN2 patients respiratory health contributes to disease burden but can be maintained by 
supportive measures
41 NA 89
CLN2 children should have all their normal childhood vaccinations or add exclusions 38 D 92
Family members, caregivers or relatives are also urged to vaccinate to lessen the risk of 
patient viral contraction
39 D 93
Table 12 Sleep and rest in CLN2 disease, statements and consensus data
Statement Responders Evidence 
level
Consensus
Insomnia and sleep disturbance are common, and this should be actively monitored and managed as 
per local practice. Fixed cushions for positioning are recommended to avoid motor restlessness, the 
risk of swallowing saliva and fear of choking
39 C 90
Maintaining proper sleep is vitally important for the patient and the caregivers; therefore it is important 
to ensure good and sufficient sleep for the whole family
41 C 95
A patient should be supported as required to continue to engage and socialise at school or other facili-
ties for as long as possible
41 D 96
Living with a rare disease is challenging to the whole family and appropriate support should be offered 
to caregivers, siblings and family members
40 D 97
Page 14 of 19Mole et al. Orphanet J Rare Dis          (2021) 16:185 
Interventions such as regular pulmonary hygiene, for 
example: using mucolytics, high-frequency chest wall 
oscillation, mechanical insufflator-exsufflator devices 
and bronchodilators, are recommended [25]. In addi-
tion, regular mobilisation in age-appropriate positions, 
and manual interventions to improve lung function 
within physiotherapy should take place. Three state-
ments were developed to support respiratory health 
recommendations.
Sleep and rest (Table 12)
Sleep and rest are equally important for the patient and 
their caregivers. Sleep deprivation due to the need to 
be constantly on alert for seizures is common for the 
caregiver. Psychopathological symptoms such as sleep 
disturbance, fear, aggressive behaviour, depression, and 
hallucinations are a particular challenge [29]. The Chil-
dren’s Sleep Habits Questionnaire is a validated tool used 
for both behaviourally and medically-based problems 
[81]. The majority of children with CLN2 disease have 
sleep disturbance [81], which in turn adversely affects 
seizure control and exacerbates behavioural [73] and cog-
nitive impairments [25]. Behavioural and environmen-
tal strategies and medications may be helpful in treating 
sleep dysfunction [25]. Sleep-disordered breathing was a 
prominent concern for families, and a polysomnogram is 
recommended for children with a sleep disturbance and 
snoring to identify a treatable concern [81]. Melatonin is 
safely and frequently used for sleep onset difficulties in 
children with neurodevelopment disorders [82], although 
its efficacy remains controversial and more evidence is 
required [83].
Four statements were developed to support the recom-
mendations for sleep and rest management.
End of life care (Table 13)
The psychological impact on caregivers whose children 
have a life-limiting disease is profound, and the pallia-
tive care team should be engaged to discuss milestone 
losses and set expectations  (Fig.  1). A palliative care 
framework for CLN2 disease management facilitates 
the comprehensive care of patients and their families 
[25]. Palliative therapies in NCL diseases represent a 
significant challenge due to multiple symptom complexes 
and affected body systems [29]. The major goal at the end 
of life is alleviation of pain and distress. Respiratory com-
fort can be improved by frequent repositioning and using 
positioning aids. If possible, the positions should be age-
appropriate to achieve the greatest possible participation 
in everyday life. Hospice and home palliative care ser-
vices should be offered, although there are regional bar-
riers to the availability of such services [25]. In the later 
stages of the disease, there should be an emphasis on 
prevention of secondary complications such as decubitus 
ulcers, muscle atrophy and aspiration pneumonia [25].
Two statements were developed to support the end of 
life care recommendations.
Discussion
Effective management and treatment of CLN2 disease 
management require an early diagnosis; and therefore, 
unless there is a familial history, irreversible neurodegen-
eration has usually occurred before a diagnosis is made 
[31].
The aim of this programme was to use a robust system-
atic approach to develop consensus-based guidelines to 
increase diagnosis rates and raise awareness about the 
management of symptoms in line with the best available 
evidence and to aid the development of expected stand-
ards of care. The approach (summarised in Addidional 
file 2) that has been used in this methodology has been 
used successfully for the development of other medi-
cal guidelines; For example, the American College of 
Medical Genetics (ACMG), interpretation of sequence 
variants [84] for the diagnosis and treatment of phenylke-
tonuria (PKU) [85], and the Maple Syrup Urine Disease 
(MSUD) guidelines [86]. It is crucial that the patient and 
family voice is heard in developing such standards and 
guidelines.
Our results highlight the critical need for early diagno-
sis and document the current expected care standards for 
laboratory, clinical and radiological diagnostic investiga-
tions and assessments. Children who present with signifi-
cant speech delay or decline and clumsiness, without a 
diagnosis, should be suspected of CLN2 disease, or other 
lysosomal storage diseases, and should be referred to a 
specialist centre.
Table 13 End of life care for CLN2 disease, statements and consensus data
Statement Responders Evidence 
level
Consensus
Important considerations as nearing ‘end-of-life care’ patient comfort, including reduction of pain and anxi-
ety as well as support for continued activities and interactions, and support for family and caregivers
41 C 98
Palliative care services are important, and a plan should be recorded and offered at the end of life, if or 
when available
39 D 96
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Economic modelling did not form part of this guideline 
development. However, there may be local cost implica-
tions of applying these guidelines which should be con-
sidered, and especially in prescribing Brineura. Economic 
modelling criteria around Brineura were requested from 
the manufacturer (BioMarin Pharmaceutical Inc.) and 
from the National Institute for Health and Care Excel-
lence, UK (NICE). These publicly available documents 
can be found in Additional file  1: Appendix  8, together 
with a Pharmacoeconomic Review Report: Cerlipo-
nase Alfa (Brineura): (BioMarin Pharmaceutical (Can-
ada) Inc.). Other health state-dependent utility values 
obtained through a utility study conducted in July 2017 
that allows for health states to incorporate all relevant 
aspects of the disease that impact the quality of life, 
including progressive symptoms that are not captured 
by the CLN2 Clinical Rating Score are not published but 
were made available to the steering committee as it was 
appreciated that costs have significant implications for 
Health Service decision making around funding and pro-
vision of novel therapies.
Start and stop eligibility criteria for enzyme replace-
ment therapies are becoming increasingly important, 
especially in the rare disease sphere. Looking at all the 
criteria available in the public domain there are some 
regional differences, although there is a general agree-
ment. These have been summarised below as a reference 
(Additional file  1: Appendix  8). These criteria were not 
part of the guideline development process, regarded as 
out of scope by the experts due to the variations in health 
care systems, cultural backgrounds, funding arrange-
ments, facilities and the heterogeneity of the disorder. 
Further, most of the publicly available stop-start criteria 
only focus on the classical early-onset form of CLN2 dis-
ease. Discussions with the family to review risks, benefits, 
and criteria for potential initiation/discontinuation of 
therapy are helpful to clearly communicate expectations 
of therapy. Quality of life data was not used in the model 
as they do not represent the full range of CLN2 disease 
stages or include equivalent data for patients treated with 
standard care; publications are planned to fill this gap.
These guidelines covers the whole spectrum of the dis-
order. They all focus on the following main areas: that 
diagnosis must be confirmed and secure before the onset 
of therapy, baseline assessment should be performed 
before the onset of treatment and may include but is not 
limited to language ability, motor ability, feeding status, 
seizures, myoclonus and vision. Individual treatment 
aims are important to be established with the family and 
accepting that stabilisation of disease at treatment onset 
may be a very important outcome for some families, as 
this condition is normally rapidly progressive. Treatment 
should be discontinued in patients if they are affected by 
another life-limiting condition, or have infusion-related 
severe adverse reactions which are not preventable/man-
ageable either by appropriate pre-medication, adjustment 
of the infusion rate, or other clinical concerns that cannot 
be resolved.
Strengths and limitations of the programme
Management of a child affected by CLN2 disease requires 
a coordinated, multidisciplinary approach. It is, there-
fore, imperative that guidelines cover a broad range of 
topics in the clinical management of this disease. The 
nature of rare diseases often results in a lack of high-
quality evidence for medical and treatment interventions. 
Therefore, each of the consensus statements here was 
also assessed by the SC chairs, using the Oxford Centre 
for Evidence-Based Medicine grading system.
While the response rate to each question was high, not 
all HCPs responded to each question. The reason for this 
is that the responders were multidisciplinary, and not all 
questions were relevant to their field of expertise. The 
multidisciplinary nature of respondents adds strength to 
the guidelines.
Multiple sponsors funded this programme; however, 
measures were taken to ensure that this did not influence 
the final statements (described in the methods section).
The strengths of this programme include the robust 
methodology, covering the initial selection of expert 
steering committee and chairs, through to the expert 
mapping tool, which has previously been presented as a 
poster [17] (Additional file 1: Appendix 2). This method 
brought together multidisciplinary experts from around 
the globe, each contributing not only the knowledge of 
the condition itself but also local challenges with regards 
to patient management. The committee included input 
from a patient advocate. The comprehensive systematic 
literature review ensured that the guidelines are based 
on the current evidence base. The use of a modified-
Delphi voting process to gain consensus ensured that 
each of the 53 guideline statements reflected the views of 
wide-ranging specialists. Risk of bias assessment was not 
undertaken for these guidelines as the aim is related to 
the identification of clinical management strategies, diag-
noses, holistic multidisciplinary care used by health care 
professionals. The purpose was not to gather information 
about the effectiveness of outcomes. The methodology 
and transparency were also demonstrated via review of 
the manuscript against the validated AGREE II instru-
ment, where the guidelines gained a score of 5.7 (www. 
agree trust. org).
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Future perspectives
Improvements in symptom management and the intro-
duction of ERT, and potentially a future gene therapy 
for treatment of CLN2 disease is likely to impose new 
challenges as life expectancy increases. In addition, fur-
ther investigation is necessary for the optimisation of 
medication regimes for seizure management and move-
ment disorder. However, due to the availability and var-
iability of drugs in different geographical areas, it was 
deemed out of scope for this consensus paper. These 
guidelines aim to refine existing strategies facilitating 
optimal care to all CLN2 disease patients while taking 
into account local boundaries. These guidelines were 
developed to be utilised internationally and as such, can 
be regarded as the basis for adaptation to local policies. 
The wide variability in health care systems, geography, 
economical and cultural differences make it impossible 
to develop audit guidance acceptable to all. A future 
aim is to identify and prioritise physicians, nurses and 
residential care staff via meeting presentations, pub-
lications, online-focused multi-audience meetings, 
and a web-site summarising these recommendations 
in an easily accessible format, linking to other NCL 
resources; and to liaise with these providers or stake-
holders, including educators and teachers, to ensure 
consistency. While out of scope for this manuscript, it 
is the hope of the steering committee that local groups 
will extract appropriate elements from these guidelines 
and develop their own implementation and audit cycles. 
Audited information would be invaluable if it could be 
fed back for incorporation into the regular reviews and 
updates to these guidelines.
Conclusions
This manuscript provides robust evidence- and con-
sensus-driven guidelines that can be used by all health-
care professionals involved in the management of 
patients with CLN2 disease. The approach that has 
been taken in the process of these recommendations 
are also applicable to the symptomatic management of 
other neurodegenerative diseases. It is recognised that 
the guidelines provided represent a point in time, and 
further research is required to address current knowl-
edge and evidence gaps, especially the emergence and 
effect of new treatments. This manuscript provides one 
element to the guidelines on the diagnosis, treatment 
and management of patients with CLN2 disease. It will 
accompany other resources with plain language sum-
maries and tools to disseminate the information across 
the medical field. It is intended that the methodology 
used in these guidelines is robust and will be easily 
transferred to the development of guidelines for other 
rare diseases. Ideally, it will be readily accessible online.
The SC recommends that these guidelines are 
reviewed and updated within five years or sooner if 
there are significant changes to medical practice; fur-
ther, to develop criteria to enable monitoring and 
auditing to assess the implementation of and adherence 
to the guidelines. The process was led by an independ-
ent steering committee and independent of sponsors 
influence.
This guideline program addresses a clinical need for 
patients with CLN2 disease and is intended to comple-
ment other information available [7, 15, 20, 25, 29, 64], 
including that of patient support organisations (See 
Additional file 1: Appendix 9).
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